Suppr超能文献

美国管理式医疗人群中非结核分枝杆菌肺病患者全因死亡率的相对风险。

Relative risk of all-cause mortality in patients with nontuberculous mycobacterial lung disease in a US managed care population.

机构信息

Department of Medicine, University Health Network and Mount Sinai Hospital, Toronto, Canada; Department of Medicine, University of Toronto, Toronto, Canada.

Public Health Research Institute, Rutgers, The State University of New Jersey, Newark, NJ, USA.

出版信息

Respir Med. 2018 Dec;145:80-88. doi: 10.1016/j.rmed.2018.10.022. Epub 2018 Oct 22.

Abstract

RATIONALE

The risk of all-cause mortality of nontuberculous mycobacterial lung disease (NTMLD) in the United States (US) population is not well established.

OBJECTIVES

This study aims to assess the public health burden of NTMLD in the US by comparing the relative risk of all-cause mortality in the NTMLD population with an age- and sex-matched cohort from the general population.

METHODS

Patients with physician claims for NTMLD (ICD-9 0.031; ICD-10 A31.0) were identified between 2007 and 2016 from a large US national managed care insurance plan covering approximately 15-18 million members annually. A control group with no NTMLD ICD-9 or 10 codes was randomly selected from the general population and matched 3:1 to the NTMLD sample according to birth year, gender, and insurance benefit coverage. The date of first NTMLD diagnosis of each patient was assigned to the matched controls as the index date. The Cox proportional hazard method compared survival between cohorts, adjusting for demographic factors and baseline comorbidities.

RESULTS

A total of 2005 patients with NTMLD and 6014 controls were identified, with a mean follow-up duration of 3.4 years and 3.7 years, respectively. The NTMLD group had substantially higher proportions of patients with asthma (23.3% versus 3.5%), bronchiectasis (36.5% versus 0.1%), COPD (52.0% versus 5.9%), arrhythmia (22.6% versus 6.5%), coronary artery disease (18.5% versus 6.6%), heart failure (11.9% versus 4.1%), and cancer (18.5% versus 5.0%). The unadjusted rate of all-cause mortality from the index date was 20.7 per 1000 person-years in the NTMLD group vs 5.6 per 1000 person-years in the control group (rate ratio = 3.73; 95% CI: 2.93-4.75). Multivariable Cox regression, adjusted for the above variables as well as all other important baseline covariates, showed a doubling risk of all-cause mortality (hazard ratio [HR] = 2.06; CI: 1.52-2.79; P < 0.001) in the NTMLD vs control group.

CONCLUSIONS

All-cause mortality, adjusted for other factors, more than doubled with NTMLD compared with an age-sex-matched control group in a large US national managed care insurance plan.

摘要

背景

美国(US)人群中非结核分枝杆菌肺病(NTMLD)的全因死亡率风险尚不清楚。

目的

本研究旨在通过比较 NTMLD 人群与一般人群中年龄和性别匹配队列的全因死亡率的相对风险,评估 NTMLD 在 US 人群中的公共卫生负担。

方法

从一家大型美国国家管理式医疗保险公司中确定了 2007 年至 2016 年间有医生声称患有 NTMLD(ICD-9 0.031;ICD-10 A31.0)的患者。从一般人群中随机选择一个没有 NTMLD ICD-9 或 10 代码的对照组,并根据出生年份、性别和保险福利覆盖范围以 3:1 的比例与 NTMLD 样本相匹配。每位患者的首次 NTMLD 诊断日期被分配给匹配的对照组作为索引日期。Cox 比例风险法比较了队列之间的生存情况,同时调整了人口统计学因素和基线合并症。

结果

共确定了 2005 例 NTMLD 患者和 6014 例对照组患者,平均随访时间分别为 3.4 年和 3.7 年。NTMLD 组患者中哮喘(23.3%比 3.5%)、支气管扩张症(36.5%比 0.1%)、COPD(52.0%比 5.9%)、心律失常(22.6%比 6.5%)、冠状动脉疾病(18.5%比 6.6%)、心力衰竭(11.9%比 4.1%)和癌症(18.5%比 5.0%)的比例显著更高。在索引日期,NTMLD 组的全因死亡率为 20.7/1000 人年,对照组为 5.6/1000 人年(比率比[RR]为 3.73;95%CI:2.93-4.75)。多变量 Cox 回归分析调整了上述变量以及所有其他重要的基线协变量后,显示 NTMLD 组的全因死亡率风险增加了一倍(危险比[HR]为 2.06;CI:1.52-2.79;P<0.001)。

结论

在一项大型美国国家管理式医疗保险公司中,与年龄和性别匹配的对照组相比,调整其他因素后,NTMLD 患者的全因死亡率增加了一倍以上。

相似文献

2
Health Care Utilization and Expenditures Following Diagnosis of Nontuberculous Mycobacterial Lung Disease in the United States.
J Manag Care Spec Pharm. 2018 Oct;24(10):964-974. doi: 10.18553/jmcp.2018.18122. Epub 2018 Jul 20.
4
Guidelines-based treatment associated with improved economic outcomes in nontuberculous mycobacterial lung disease.
J Med Econ. 2019 Nov;22(11):1126-1133. doi: 10.1080/13696998.2019.1620243. Epub 2019 Jun 10.
8
Symptom Burden and Medication Use Among Patients with Nontuberculous Mycobacterial Lung Disease.
Chronic Obstr Pulm Dis. 2021 Apr 27;8(2):243-254. doi: 10.15326/jcopdf.2020.0184.
9
Deaths Related to Nontuberculous Mycobacterial Infections in the United States, 1999-2014.
Ann Am Thorac Soc. 2016 Nov;13(11):1951-1955. doi: 10.1513/AnnalsATS.201606-474BC.
10
Nontuberculous mycobacterial lung disease in a high tuberculosis incidence setting in Brazil.
J Bras Pneumol. 2018 Apr;44(2):106-111. doi: 10.1590/s1806-37562017000000213.

引用本文的文献

3
Intrapulmonary pharmacokinetics of SPR719 following oral administration of SPR720 to healthy volunteers.
Antimicrob Agents Chemother. 2024 Nov 6;68(11):e0110324. doi: 10.1128/aac.01103-24. Epub 2024 Oct 1.
4
Drug-drug interactions in the management of non-tuberculous mycobacterial infections.
Front Microbiol. 2024 Sep 5;15:1468383. doi: 10.3389/fmicb.2024.1468383. eCollection 2024.
6
7
Nontuberculous mycobacterial pulmonary disease added burden to COPD and bronchiectasis in Japan.
ERJ Open Res. 2024 Jul 8;10(4). doi: 10.1183/23120541.00911-2023. eCollection 2024 Jul.
8
Gut microbiota dysbiosis-related susceptibility to nontuberculous mycobacterial lung disease.
Gut Microbes. 2024 Jan-Dec;16(1):2361490. doi: 10.1080/19490976.2024.2361490. Epub 2024 Jun 11.
9
Mortality Risk in Bronchiectasis.
Arch Bronconeumol. 2024 Jun;60(6):333-335. doi: 10.1016/j.arbres.2024.04.006. Epub 2024 Apr 24.

本文引用的文献

1
The risk of mycobacterial infections associated with inhaled corticosteroid use.
Eur Respir J. 2017 Sep 20;50(3). doi: 10.1183/13993003.00037-2017. Print 2017 Sep.
2
Burden of non-tuberculous mycobacterial pulmonary disease in Germany.
Eur Respir J. 2017 Apr 26;49(4). doi: 10.1183/13993003.02109-2016. Print 2017 Apr.
3
Obesity/overweight reduces the risk of active tuberculosis: a nationwide population-based cohort study in Taiwan.
Int J Obes (Lond). 2017 Jun;41(6):971-975. doi: 10.1038/ijo.2017.64. Epub 2017 Mar 10.
4
Pulmonary Nontuberculous Mycobacteria-Associated Deaths, Ontario, Canada, 2001-2013.
Emerg Infect Dis. 2017 Mar;23(3):468-476. doi: 10.3201/eid2303.161927.
5
On the Reportability of Nontuberculous Mycobacterial Disease to Public Health Authorities.
Ann Am Thorac Soc. 2017 Mar;14(3):314-317. doi: 10.1513/AnnalsATS.201610-802PS.
6
Concomitant Medication Use and New-Onset Diabetes Among Medicaid Beneficiaries with Chronic Obstructive Pulmonary Disease.
Popul Health Manag. 2017 Jun;20(3):224-232. doi: 10.1089/pop.2016.0047. Epub 2016 Sep 30.
7
Deaths Related to Nontuberculous Mycobacterial Infections in the United States, 1999-2014.
Ann Am Thorac Soc. 2016 Nov;13(11):1951-1955. doi: 10.1513/AnnalsATS.201606-474BC.
8
Mortality among patients with pulmonary non-tuberculous mycobacteria disease.
Int J Tuberc Lung Dis. 2016 May;20(5):582-7. doi: 10.5588/ijtld.15.0807.
9
Mycobacterium abscessus Complex Infections in Humans.
Emerg Infect Dis. 2015 Sep;21(9):1638-46. doi: 10.3201/2109.141634.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验